利伐沙班(拜瑞妥)2024年的价格是多少钱一盒?

The price of Rivaroxaban (Xarelto) in 2024

Currently, it is understood that the price of Rivaroxaban (Xarelto) is about $300-500, and the price of the drug is not fixed due to various factors.

Purchase channels for Rivaroxaban (Xarelto)

You can purchase it with the help of domestic hospital pharmacies, retail pharmacies, online pharmacies, overseas medical service institutions, etc.

1. Domestic hospital pharmacies:

Patients can be seen in the hospital, and the doctor will evaluate whether Rivaroxaban (Xarelto) is suitable for use based on the actual condition, and then issue a prescription. You can buy the medicine in the hospital pharmacy based on the doctor's prescription. Please consult the hospital pharmacy staff for specific prices.

2. Retail pharmacies

You can consult local retail pharmacies to see if Rivaroxaban (Xarelto) is sold. However, the conditions and environments in each region are different, and the price of the drug will be different. The specific price is subject to the local pharmacy.

3. Online pharmacies

Patients can also consult online pharmacies. Some online pharmacies can deliver medicines to their doorsteps, but they need to find a regular online pharmacy to prevent being deceived.

4. Overseas medical service institutions

Patients can also obtain it through the help of domestic professional overseas medical service institutions. Usually there are many versions to choose from. Regular institutions can sign drug contracts to ensure they are genuine, but you need to find a qualified institution to avoid being deceived.

The role of rivaroxaban (Xarelto)

Rivaroxaban is an oral anticoagulant that interrupts the coagulation waterfall by inhibiting FXa, inhibits the generation of thrombin and thrombosis, and then exerts an anticoagulant effect. Rivaroxaban can prevent the formation of venous thrombosis in patients who require hip or knee replacement surgery. If the patient has venous thrombosis, the use of rivaroxaban tablets can reduce the patient's risk of pulmonary embolism. It should be noted that rivaroxaban tablets need to be taken under the guidance of a doctor, and patients cannot take them blindly on their own. If you want to know the usage and dosage of rivaroxaban, you can click to learn more.

Therapeutic efficacy of rivaroxaban (Xarelto)

In a multicenter, parallel-group, open-label, randomized study, 107 pediatric hospitals in 28 countries evaluated patients with acute venous hemorrhage who had begun heparinizing therapy. Children with embolism (aged 0 to 17 years) were assigned (2:1) to receive a weight-adjusted 20-mg equivalent dose of rivaroxaban (Xarelto) (tablets or suspension) or standard anticoagulation (heparin or a switch to a vitamin K antagonist). Randomization was performed by age and site of venous thromboembolism. The primary treatment period is 3 months (1 month in children younger than 2 years with catheter-related venous thromboembolism).

Results

Of the 520 children screened for eligibility, 500 (96%) were enrolled. After a median follow-up of 91 days (IQR 87-95) and 31 days (IQR 29-35), 4 (1%) of 335 children receiving rivaroxaban (Xarelto) developed symptomatic recurrent venous thromboembolism, and 5 (3%) of 165 children (3%) receiving standard anticoagulants developed symptomatic recurrent venous thromboembolism.

Repeated imaging showed improved effects of rivaroxaban on clot load compared with standard anticoagulants. Major or clinically relevant nonmajor bleeding occurred in 10 of 329 children (3%) who received rivaroxaban (all nonmajor bleeding); major or clinically relevant nonmajor bleeding occurred in 3 of 162 children (2%) who received standard anticoagulants. Estimates of the absolute and relative efficacy and safety of rivaroxaban (Xarelto) relative to standard anticoagulants were similar to those reported in studies of rivaroxaban in adults. There were no treatment-related deaths.

In pediatric patients with acute venous thromboembolism, treatment with rivaroxaban (Xarelto) was associated with a lower risk of recurrence and a reduced burden of thrombosis without increasing bleeding compared with standard anticoagulants.

The above information is integrated from the Internet and the US FDA drug instructions. It is for reference only. It is recommended to follow the doctor's advice and not to use it blindly.

Related hot articles:

References

Male C, Lensing AWA, Palumbo JS, Kumar R, Nurmeev I, Hege K, Bonnet D, Connor P, Hooimeijer HL, Torres M, Chan AKC, Kenet G, Holzhauer S, Santamaría A, Amedro P, Chalmers E, Simioni P, Bhat RV, Yee DL, Lvova O, Beyer-Westendorf J, Biss TT, Martinelli I, Saracco P, Peters M, Kállay K, Gauger CA, Massicotte MP, Young G, Pap AF, Majumder M, Smith WT, Heubach JF, Berkowitz SD, Thelen K, Kubitza D, Crowther M, Prins MH, Monagle P; EINSTEIN-Jr Phase 3 Investigators. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomized, controlled, phase 3 trial. Lancet Haematol. 2020 Jan;7(1):e18-e27. doi: 10.1016/S2352-3026(19)30219-4. Epub 2019 Nov 5. PMID: 31699660.